Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2011 (2011), Article ID 174019, 9 pages
http://dx.doi.org/10.1155/2011/174019
Research Article

Metabolomic Characterization of Ovarian Epithelial Carcinomas by HRMAS-NMR Spectroscopy

1Biophysics and Nuclear Medicine Department, University Hospitals of Strasbourg, 67098 Strasbourg, France
2University of Strasbourg, CNRS LINC UMR 7237, 67081 Strasbourg, France
3University of Strasbourg, Institute of Chemistry, CNRS UMR 7177, 67081 Strasbourg, France
4Pathology Department, University Hospitals of Strasbourg, 67098, France
5Bruker BioSpin, 67160 Wissembourg, France

Received 10 November 2010; Revised 3 February 2011; Accepted 28 February 2011

Academic Editor: Nelson N. H. Teng

Copyright © 2011 D. Ben Sellem et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, E. Ward et al., “Cancer statistics, 2006,” CA: A Cancer Journal for Clinicians, vol. 56, no. 2, pp. 106–130, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Podo, F. Sardanelli, E. Iorio et al., “Abnormal choline phospholipid metabolism in breast and ovary cancer: molecular bases noninvasive imaging approaches,” Current Medical Imaging Reviews, vol. 3, no. 2, pp. 123–137, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Simcock, D. Neesham, M. Quinn, E. Drummond, A. Milner, and R. J. Hicks, “The impact of PET/CT in the management of recurrent ovarian cancer,” Gynecologic Oncology, vol. 103, no. 1, pp. 271–276, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Russell, “Ovarian epithelial tumours with atypical proliferation,” in Advances in Gynaecological Pathology, D. Lowe and H. Fox, Eds., pp. 299–320, Churchill Livingstone, Edinburgh, UK, 1992. View at Google Scholar
  5. W. B. Mackinnon, P. Russell, G. L. May, and C. E. Mountford, “Characterization of human ovarian epithelial tumors (ex vivo) by proton magnetic resonance spectroscopy,” International Journal of Gynecological Cancer, vol. 5, no. 3, pp. 211–221, 1995. View at Publisher · View at Google Scholar · View at Scopus
  6. J. C. Wallace, G. P. Raaphorst, R. L. Somorjai et al., “Classification of H MR spectra of biopsies from untreated and recurrent ovarian cancer using linear discriminant analysis,” Magnetic Resonance in Medicine, vol. 38, no. 4, pp. 569–576, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. L. F. A. G. Massuger, P. B. J. Van Vierzen, U. Engelke, A. Heerschap, and R. Wevers, “H-magnetic resonance spectroscopy: a new technique to discriminate benign from malignant ovarian tumors,” Cancer, vol. 82, no. 9, pp. 1726–1730, 1998. View at Google Scholar · View at Scopus
  8. E. A. Boss, S. H. Moolenaar, L. F. A. G. Massuger et al., “High-resolution proton nuclear magnetic resonance spectroscopy of ovarian cyst fluid,” NMR in Biomedicine, vol. 13, no. 5, pp. 297–305, 2000. View at Google Scholar
  9. E. Kolwijck, U. F. Engelke, M. Van Der Graaf et al., “N-acetyl resonances in in vivo and in vitro NMR spectroscopy of cystic ovarian tumors,” NMR in Biomedicine, vol. 22, no. 10, pp. 1093–1099, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Iorio, D. Mezzanzanica, P. Alberti et al., “Alterations of choline phospholipid metabolism in ovarian tumor progression,” Cancer Research, vol. 65, no. 20, pp. 9369–9376, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Hascalik, O. Celik, K. Sarac, A. Alkan, and B. Mizrak, “Clinical significance of N-acetyl-L-aspartate resonance in ovarian mucinous cystadenoma,” International Journal of Gynecological Cancer, vol. 16, no. 1, pp. 423–426, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. S. J. Booth, M. D. Pickles, and L. W. Turnbull, “In vivo magnetic resonance spectroscopy of gynaecological tumours at 3.0 Tesla,” An International Journal of Obstetrics and Gynaecology, vol. 116, no. 2, pp. 300–303, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Stanwell, P. Russell, J. Carter, S. Pather, S. Heintze, and C. Mountford, “Evaluation of ovarian tumors by proton magnetic resonance spectroscopy at three tesla,” Investigative Radiology, vol. 43, no. 10, pp. 745–751, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. M. A. McLean, A. N. Priest, I. Joubert et al., “Metabolic characterization of primary and metastatic ovarian cancer by H-MRS in vivo at 3T,” Magnetic Resonance in Medicine, vol. 62, no. 4, pp. 855–861, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. International Federation of Gynecology and Obstetrics, “Classification and staging of malignant tumours in the female pelvis,” Acta Obstetricia et Gynecologica Scandinavica, vol. 50, pp. 1–7, 1971. View at Google Scholar
  16. Y. Shimizu, S. Kamoi, S. Amada, K. Hasumi, F. Akiyama, and S. G. Silverberg, “Toward the development of a universal grading system for ovarian epithelial carcinoma I. Prognostic significance of histopathologic features-problems involved in the architectural grading system,” Gynecologic Oncology, vol. 70, no. 1, pp. 2–12, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Piotto, F. M. Moussallieh, B. Dillmann et al., “Metabolic characterization of primary human colorectal cancers using high resolution magic angle spinning H magnetic resonance spectroscopy,” Metabolomics, vol. 5, no. 3, pp. 292–301, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Akoka, L. Barantin, and M. Trierweiler, “Concentration measurement by proton NMR using the ERETIC method,” Analytical Chemistry, vol. 71, no. 13, pp. 2554–2557, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Wider and L. Dreier, “Measuring protein concentrations by NMR spectroscopy,” Journal of the American Chemical Society, vol. 128, no. 8, pp. 2571–2576, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Tenenhaus, La Regression PLS. Théorie et Pratique, Editions Technip, Paris, France, 1998.
  21. M. H. Baslow, “N-acetylaspartate in the vertebrate brain: metabolism and function,” Neurochemical Research, vol. 28, no. 6, pp. 941–953, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. A. P. Burlina, V. Ferrari, L. Facci, S. D. Skaper, and A. B. Burlina, “Mast cells contain large quantities of secretagogue-sensitive N-acetylaspartate,” Journal of Neurochemistry, vol. 69, no. 3, pp. 1314–1317, 1997. View at Google Scholar · View at Scopus
  23. M. H. Baslow and S. Yamada, “Identification of N-acetylaspartate in the lens of the vertebrate eye: a new model for the investigation of the function of N-acetylated amino acids in vertebrates,” Experimental Eye Research, vol. 64, no. 2, pp. 283–286, 1997. View at Google Scholar · View at Scopus
  24. M. L. Schiebler, K. K. Miyamoto, M. White, S. J. Maygarden, and J. L. Mohler, “In vitro high resolution H-spectroscopy of the human prostate: benign prostatic hyperplasia, normal peripheral zone and adenocarcinoma,” Magnetic Resonance in Medicine, vol. 29, no. 3, pp. 285–291, 1993. View at Google Scholar · View at Scopus
  25. W. B. Mackinnon, L. Huschtscha, K. Dent, R. Hancock, C. Paraskeva, and C. E. Mountford, “Correlation of cellular differentiation in human colorectal carcinoma and adenoma cells lines with metabolite profiles determined by H magnetic resonance spectroscopy,” International Journal of Cancer, vol. 59, no. 2, pp. 248–261, 1994. View at Publisher · View at Google Scholar · View at Scopus
  26. M. M. Mahon, A. D. Williams, W. P. Soutter et al., “H magnetic resonance spectroscopy of invasive cervical cancer: an in vivo study with ex vivo corroboration,” NMR in Biomedicine, vol. 17, no. 1, pp. 1–9, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. C. E. Mountford, S. Ramadan, P. Stanwell, and P. Malycha, “Proton MRS of the breast in the clinical setting,” NMR in Biomedicine, vol. 22, no. 1, pp. 54–64, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Sitter, T. Bathen, B. Hagen, C. Arentz, F. E. Skjeldestad, and I. S. Gribbestad, “Cervical cancer tissue characterized by high-resolution magic angle spinning MR spectroscopy,” Magnetic Resonance Materials in Physics, Biology and Medicine, vol. 16, no. 4, pp. 174–181, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. I. S. Gribbestad, S. B. Petersen, H. E. Fjøsne, S. Kvinnsland, and J. Krane, “1H NMR spectroscopic characterization of perchloric acid extracts from breast carcinomas and non-involved breast tissue,” NMR in Biomedicine, vol. 7, no. 4, pp. 181–194, 1994. View at Google Scholar · View at Scopus
  30. I. S. Gribbestad, T. E. Singstad, G. Nilsen et al., “In vivo H MRS of normal breast and breast tumors using a dedicated double breast coil,” Journal of Magnetic Resonance Imaging, vol. 8, no. 6, pp. 1191–1197, 1998. View at Google Scholar · View at Scopus
  31. S. Makhija, N. Howden, R. Edwards, J. Kelley, D. W. Townsend, and C. C. Meltzer, “Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review,” Gynecologic Oncology, vol. 85, no. 1, pp. 53–58, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. M. J. García-Velloso, M. Jurado, C. Ceamanos et al., “Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 9, pp. 1396–1405, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. M. M. Thrall, J. A. DeLoia, H. Gallion, and N. Avril, “Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer,” Gynecologic Oncology, vol. 105, no. 1, pp. 17–22, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Nanni, D. Rubello, M. Farsad et al., “18F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients,” European Journal of Surgical Oncology, vol. 31, no. 7, pp. 792–797, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Takekuma, M. Maeda, T. Ozawa, K. Yasumi, and T. Torizuka, “Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer,” International Journal of Clinical Oncology, vol. 10, no. 3, pp. 177–181, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. B. Simcock, D. Neesham, M. Quinn, E. Drummond, A. Milner, and R. J. Hicks, “The impact of PET/CT in the management of recurrent ovarian cancer,” Gynecologic Oncology, vol. 103, no. 1, pp. 271–276, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. I. C. P. Smith and D. E. Blandford, “Diagnosis of cancer in humans by H NMR of tissue biopsies,” Biochemistry and Cell Biology, vol. 76, no. 2-3, pp. 472–476, 1998. View at Google Scholar · View at Scopus
  38. A. Moreno and C. Arús, “Quantitative and qualitative characterization of H NMR spectra of colon tumors, normal mucosa and their perchloric acid extracts: decreased levels of myo-inositol in tumours can be detected in intact biopsies,” NMR in Biomedicine, vol. 9, no. 1, pp. 33–45, 1996. View at Google Scholar · View at Scopus
  39. A. Imperiale, K. Elbayed, F. Moussallieh et al., “Metabolomic pattern of childhood neuroblastoma obtained by 1H-high-resolution magic angle spinning (HRMAS) NMR spectroscopy,” Pediatric Blood and Cancer, vol. 56, no. 1, pp. 24–34, 2011. View at Publisher · View at Google Scholar
  40. S. L. Pelech and D. E. Vance, “Signal transductin via phosphatidylcholine cycles,” Trends in Biochemical Sciences, vol. 14, no. 1, pp. 28–30, 1989. View at Google Scholar · View at Scopus
  41. K. Glunde, E. Ackerstaff, K. Natarajan, D. Artemov, and Z. M. Bhujwalla, “Real-time changes in H1 and P31 NMR spectra of malignant human mammary epithelial cells during treatment with the anti-inflammatory agent indomethacin,” Magnetic Resonance in Medicine, vol. 48, no. 5, pp. 819–825, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. E. Ackerstaff, K. Glunde, and Z. M. Bhujwalla, “Choline phospholipid metabolism: a target in cancer cells?” Journal of Cellular Biochemistry, vol. 90, no. 3, pp. 525–533, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. S. J. Booth, M. D. Pickles, and L. W. Turnbull, “In vivo magnetic resonance spectroscopy of gynaecological tumours at 3.0 Tesla,” An International Journal of Obstetrics and Gynaecology, vol. 116, no. 2, pp. 300–303, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Okada, M. Harada, K. Matsuzaki, H. Nishitani, and T. Aono, “Evaluation of female intrapelvic tumors by clinical proton MR spectroscopy,” Journal of Magnetic Resonance Imaging, vol. 13, no. 6, pp. 912–917, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Friedlander, “Drug resistance in ovarian cancer,” International Journal of Gynecological Cancer, vol. 1, supplement, pp. 2–9, 1992. View at Google Scholar
  46. T. F. Bathen, B. Sitter, T. E. Sjøbakk, M.-B. Tessem, and I. S. Gribbestad, “Magnetic resonance metabolomics of intact tissue: a biotechnological tool in cancer diagnostics and treatment evaluation,” Cancer Research, vol. 70, no. 17, pp. 6692–6696, 2010. View at Publisher · View at Google Scholar